The FDA's approval of pirtobrutinib (Jaypirca) has expanded options for patients with relapsed or refractory CLL/SLL, offering a non-covalent BTK inhibitor that can remain effective even after a ...

Stage-specific EBV miRNA patterns may help distinguish early from advanced CLL and inform disease biology. EBV-encoded microRNAs (miRNAs) demonstrated distinct associations with clinical stage in ...

Not long ago, treatment for chronic lymphocytic leukemia (CLL) often meant needing chemotherapy or a targeted medication for the rest of your life, as long as you tolerated it and your doctor could ...

Experts weigh continuous vs time‑limited CLL therapy, compare acalabrutinib and zanubrutinib, and debate when pirtobrutinib ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Two patients with chronic lymphocytic leukemia (CLL) can face very different futures. One may live for decades without ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

The partnership has so far provided Brukinsa to over 300 CLL patients in Armenia, Ethiopia, and Nepal.

ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...

CAR T-cell adverse-event monitoring/management in MCL was reported suboptimal by 54%, peaking in Germany and Brazil community practices, whereas BTK inhibitor management gaps in MCL affected 30%.

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Andrew Evens, DO & Joanna Rhodes, MD on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering ...